Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.93 |
| ▸ | CCND1 | P24385 | 13/20 | 0.93 |
| ▸ | CCND2 | P30279 | 13/20 | 0.93 |
| ▸ | CCND3 | P30281 | 13/20 | 0.93 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 6/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 6/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | WEE1 | P30291 | 1/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263418 | 0.96 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5263834 | 0.95 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5262381 | 0.95 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5267105 | 0.86 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| Hydrochloric Acid SCHEMBL30241083 | 0.84 | CDK4 (0.78) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL4353287 | 0.84 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5264440 | 0.83 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5266223 | 0.83 | CDK4 (0.77) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL19604934 | 0.82 | CCND1 (0.75) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL5263951 | 0.82 | CCND1 (0.74) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | claimed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | claimed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.